Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7937976 | 0.90 | MAT2A (0.34) | NPC1RAB9APTPN5 | |
| SCHEMBL7570384 | 0.90 | NPC1 (0.45) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL29184833 | 0.88 | NPC1 (0.41) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL23636595 | 0.86 | NPC1 (0.42) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL28904542 | 0.85 | NPC1 (0.42) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL7592852 | 0.83 | NPC1 (0.42) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL28595118 | 0.83 | PTPN5 (0.36) | NPC1RAB9ALMNAPOLBKDM4E | |
| SCHEMBL18375140 | 0.80 | NPC1 (0.45) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL8204058 | 0.80 | NPC1 (0.48) | NPC1RAB9ALMNAPOLBIDH1 | |
| SCHEMBL4265490 | 0.80 | NPC1 (0.39) | NPC1RAB9ALMNAPOLBIDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323502-B2 | A polypropylene with a synergistic mixture of sterically hindered stabilizers and a phosphazene flame retardant; antimony-free | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20030220422-A1 | Flame retardant compositions | CIBA SPECIALTY CHEMICALS CORP. | 2003-11-27 | — | — | US | disclosed |
| US-20010020099-A1 | Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith | GALBO JAMES P (US) | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020099-A1 | Hydroxy-substituted N-alkoxy hindered amines and compositions stabilized therewith | POLH, OGG1, OGFOD1 | NPC1 1790/4885RAB9A 2188/4885LMNA 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.